Barbara Angehrn Pavik, Asceneuron CEO
Alzheimer's biotech Asceneuron raises $100M to see if it can compete with Lilly, Biogen on tau
A small Swiss biotech has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
